Department of Oncology, Shanxi Provincial People's Hospital, Taiyuan, 030012, China.
Pulmonary and Critical Care Medicine, Shanxi Provincial People's Hospital, Shanxi, China.
Invest New Drugs. 2022 Oct;40(5):1160-1163. doi: 10.1007/s10637-022-01260-4. Epub 2022 May 24.
ALK (anaplastic lymphoma kinase) gene rearrangements have been reported in 3-5% of NSCLC patients. Different ALK fusion forms can mediate different downstream signaling pathways and may exhibit different sensitivities to ALK tyrosine kinase inhibitors (TKIs). To identify more fusion partners that are sensitive to ALK-TKIs, we present a case of 46-year-old woman with stage IV lung adenocarcinoma. NGS panel analysis suggested that a novel SSFA2-ALK fusion was identified in this patient. Moreover, this fusion was validated through IHC (VENTANA ALK (D5F3) antibody) and FISH (ZytoLight ALK Break Apart FISH Probe). Importantly, to the best of our knowledge, there is no report about SSFA2-ALK fusion in solid cancers. Moreover, the patient achieved an admirable response to alectinib, with a clinical evaluation of complete response (CR). In summary, our findings expand the spectrum of ALK fusion patterns and provide robust evidence for the precise administration of alectinib in the future.
ALK（间变性淋巴瘤激酶）基因重排在 3-5%的 NSCLC 患者中被报道。不同的 ALK 融合形式可以介导不同的下游信号通路，并可能对 ALK 酪氨酸激酶抑制剂（TKI）表现出不同的敏感性。为了鉴定对 ALK-TKI 更敏感的融合伙伴，我们呈现了一例 46 岁的 IV 期肺腺癌女性患者。NGS 小组分析提示该患者存在新型 SSFA2-ALK 融合。此外，该融合通过免疫组化（VENTANA ALK（D5F3）抗体）和 FISH（ZytoLight ALK 断裂分离 FISH 探针）得到了验证。重要的是，据我们所知，在实体肿瘤中尚无 SSFA2-ALK 融合的报道。此外，该患者对阿来替尼有令人钦佩的反应，临床评估为完全缓解（CR）。总之，我们的发现扩展了 ALK 融合模式的范围，并为未来阿来替尼的精确治疗提供了有力证据。
